- Home
- ECOR vs KLRS Comparison
ECOR vs KLRS Comparison
Compare ECOR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | KLRS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 46.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ECOR | KLRS |
|---|---|---|
| Price | $5.00 | $8.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $25.50 | $20.67 |
| AVG Volume (30 Days) | 41.6K | ★ 170.2K |
| Earning Date | 11-05-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,835,000.00 | N/A |
| Revenue This Year | $28.61 | N/A |
| Revenue Next Year | $41.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.90 | N/A |
| 52 Week Low | $4.16 | $2.14 |
| 52 Week High | $19.49 | $12.90 |
Technical Indicators
Market Signals| Indicator | ECOR | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 51.92 |
| Support Level | $4.42 | $7.92 |
| Resistance Level | $4.96 | $9.09 |
| Average True Range (ATR) | 0.32 | 0.94 |
| MACD | 0.05 | -0.22 |
| Stochastic Oscillator | 100.00 | 10.47 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.